BGLC vs BLK · rev $99.0K vs P/E 27, rev $24.22B
BioNexus Gene Lab Corp Common stock (BGLC) versus BlackRock Inc (BLK) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
BlackRock Inc (BLK) is a asset management company listed on NYSE. It is led by Larry Fink.
Latest reported BGLC revenue for 2026-06-30 was $99.0K. Net income was -$830.0K. BGLC currently screens at market cap $6.1M.
Latest reported BLK revenue for 2025-12-31 was $24.22B. Net income was $5.55B. Revenue was up 89.3% from 2024-12-31 to 2025-12-31. BLK currently screens at market cap $172.19B and trailing P/E 26.6.
BGLC currently screens at market cap $6.1M. BLK currently screens at market cap $172.19B and trailing P/E 26.6.
Not investment advice. Open the BGLC and BLK stock pages for the full models.
Not investment advice.